NBL-020 / CSPC Pharma - LARVOL DELTA

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: NovaRock Biotherapeutics, Ltd | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Apr 2025 ➔ Aug 2025

Metastases • Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology • Solid Tumor

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: NovaRock Biotherapeutics, Ltd | Not yet recruiting ➔ Recruiting | Initiation date: May 2023 ➔ Aug 2023

Enrollment open • Metastases • Trial initiation date • Hematological Malignancies • Oncology • TNFA • TNFRSF1B

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: NovaRock Biotherapeutics, Ltd

Metastases • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor • TNFA • TNFRSF1B

FDA clears IND for NBL-020 for advanced solid tumors (Bioworld) - "The FDA has cleared an IND for a clinical trial in the U.S. of NBL-020, a fully human antibody drug independently developed by CSPC Pharmaceutical Group Ltd.'s subsidiary Novarock Biotherapeutics Ltd., for the treatment of advanced solid tumors."

IND • Oncology • Solid Tumor